AD Pipeline Watch: Bambusa’s BBT001 Advances to Patient Dosing
BBT001, Bambusa Therapeutics’ investigational atopic dermatitis (AD) candidate, performed well in the single-ascending dose part of its ongoing Phase I healthy volunteer study.
Category: Atopic Dermatitis